These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
267 related articles for article (PubMed ID: 26825470)
1. Effects of eicosapentaenoic acid and docosahexaenoic acid on lipoproteins in hypertriglyceridemia. Patel AA; Budoff MJ Curr Opin Endocrinol Diabetes Obes; 2016 Apr; 23(2):145-9. PubMed ID: 26825470 [TBL] [Abstract][Full Text] [Related]
2. The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia. Backes J; Anzalone D; Hilleman D; Catini J Lipids Health Dis; 2016 Jul; 15(1):118. PubMed ID: 27444154 [TBL] [Abstract][Full Text] [Related]
3. Eicosapentaenoic Acid Versus Docosahexaenoic Acid as Options for Vascular Risk Prevention: A Fish Story. Singh S; Arora RR; Singh M; Khosla S Am J Ther; 2016; 23(3):e905-10. PubMed ID: 25828517 [TBL] [Abstract][Full Text] [Related]
4. Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia. McKenney JM; Sica D Pharmacotherapy; 2007 May; 27(5):715-28. PubMed ID: 17461707 [TBL] [Abstract][Full Text] [Related]
9. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia. Durrington PN; Bhatnagar D; Mackness MI; Morgan J; Julier K; Khan MA; France M Heart; 2001 May; 85(5):544-8. PubMed ID: 11303007 [TBL] [Abstract][Full Text] [Related]
10. Omega-3 Fatty Acid Formulations in Cardiovascular Disease: Dietary Supplements are Not Substitutes for Prescription Products. Fialkow J Am J Cardiovasc Drugs; 2016 Aug; 16(4):229-239. PubMed ID: 27138439 [TBL] [Abstract][Full Text] [Related]
11. The effect of a 12-week course of omega-3 polyunsaturated fatty acids on lipid parameters in hypertriglyceridemic adult HIV-infected patients undergoing HAART: a randomized, placebo-controlled pilot trial. Peters BS; Wierzbicki AS; Moyle G; Nair D; Brockmeyer N Clin Ther; 2012 Jan; 34(1):67-76. PubMed ID: 22212377 [TBL] [Abstract][Full Text] [Related]
13. Omega-3 fatty acids and cardiovascular disease: new developments and applications. Harris WS; Dayspring TD; Moran TJ Postgrad Med; 2013 Nov; 125(6):100-13. PubMed ID: 24200766 [TBL] [Abstract][Full Text] [Related]
14. Update on marine omega-3 fatty acids: management of dyslipidemia and current omega-3 treatment options. Weintraub H Atherosclerosis; 2013 Oct; 230(2):381-9. PubMed ID: 24075771 [TBL] [Abstract][Full Text] [Related]
15. New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease. Preston Mason R Curr Atheroscler Rep; 2019 Jan; 21(1):2. PubMed ID: 30637567 [TBL] [Abstract][Full Text] [Related]
16. Can pleiotropic effects of eicosapentaenoic acid (EPA) impact residual cardiovascular risk? Nelson JR; True WS; Le V; Mason RP Postgrad Med; 2017 Nov; 129(8):822-827. PubMed ID: 28974128 [TBL] [Abstract][Full Text] [Related]
17. Long-term safety and efficacy of TAK-085 in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: the omega-3 fatty acids randomized long-term (ORL) study. Tatsuno I; Saito Y; Kudou K; Ootake J J Clin Lipidol; 2013; 7(6):615-25. PubMed ID: 24314359 [TBL] [Abstract][Full Text] [Related]
18. Drug therapy for hypertriglyceridemia: fibrates and omega-3 fatty acids. Toth PP; Dayspring TD; Pokrywka GS Curr Atheroscler Rep; 2009 Jan; 11(1):71-9. PubMed ID: 19080732 [TBL] [Abstract][Full Text] [Related]
19. Icosapent ethyl for the treatment of hypertriglyceridemia. Ballantyne CM; Braeckman RA; Soni PN Expert Opin Pharmacother; 2013 Jul; 14(10):1409-16. PubMed ID: 23701295 [TBL] [Abstract][Full Text] [Related]
20. History and future of omega-3 fatty acids in cardiovascular disease. Sperling LS; Nelson JR Curr Med Res Opin; 2016; 32(2):301-11. PubMed ID: 26566071 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]